Amneal Pharmaceuticals (AMRX) Asset Writedowns and Impairment (2017 - 2026)

Amneal Pharmaceuticals' Asset Writedowns and Impairment history runs 10 years deep, the most recent figure standing at $13.4 million for Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment fell 43.58% year-over-year to $13.4 million in Q1 2026; TTM through Mar 2026 was $36.1 million, a 2069.09% increase from a year earlier, with the FY2025 full-year figure at $22.8 million, up 2376.52% from the prior year.
• Asset Writedowns and Impairment climbed to $13.4 million in Q1 2026 per AMRX's latest filing, from -$16000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $41.8 million in Q2 2023 and bottomed at -$62.7 million in Q4 2024.
• The 5-year median for Asset Writedowns and Impairment is $14.2 million (2022), against an average of $10.1 million.
• Across the five-year window, Asset Writedowns and Impairment soared 315.2% in 2023 and sank 708.95% in 2024, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at -$4.8 million in 2022, then surged by 315.2% to $10.3 million in 2023, then slumped by 708.95% to -$62.7 million in 2024, then surged by 99.97% to -$16000.0 in 2025, then jumped by 83556.25% to $13.4 million in 2026.
• Per Business Quant, the three latest AMRX Asset Writedowns and Impairment figures stand at $13.4 million (Q1 2026), -$16000.0 (Q4 2025), and $22.8 million (Q3 2025).